GT200200081A - Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11.0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma - Google Patents

Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11.0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma

Info

Publication number
GT200200081A
GT200200081A GT200200081A GT200200081A GT200200081A GT 200200081 A GT200200081 A GT 200200081A GT 200200081 A GT200200081 A GT 200200081A GT 200200081 A GT200200081 A GT 200200081A GT 200200081 A GT200200081 A GT 200200081A
Authority
GT
Guatemala
Prior art keywords
triazatetraciclo
pharmaceutical compositions
same
pentaene
hexadeca
Prior art date
Application number
GT200200081A
Other languages
English (en)
Spanish (es)
Inventor
Philip James Johnson
Peter Robert Rose
Lewin Teophilus Wint
Glenn Robert Williams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200200081(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200200081A publication Critical patent/GT200200081A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
GT200200081A 2001-05-14 2002-05-09 Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11.0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma GT200200081A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29086301P 2001-05-14 2001-05-14

Publications (1)

Publication Number Publication Date
GT200200081A true GT200200081A (es) 2003-04-22

Family

ID=23117854

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200081A GT200200081A (es) 2001-05-14 2002-05-09 Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11.0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma

Country Status (37)

Country Link
US (1) US6787549B2 (en, 2012)
EP (1) EP1390366B1 (en, 2012)
JP (1) JP4137645B2 (en, 2012)
KR (1) KR20040008175A (en, 2012)
CN (1) CN1509288A (en, 2012)
AP (1) AP1429A (en, 2012)
AR (1) AR035889A1 (en, 2012)
AT (1) ATE303386T1 (en, 2012)
BG (1) BG108344A (en, 2012)
CA (1) CA2446988A1 (en, 2012)
CZ (1) CZ20032917A3 (en, 2012)
DE (1) DE60205888T2 (en, 2012)
DO (1) DOP2002000390A (en, 2012)
DZ (1) DZ3503A1 (en, 2012)
EA (1) EA005529B1 (en, 2012)
EE (1) EE200300557A (en, 2012)
ES (1) ES2245731T3 (en, 2012)
GT (1) GT200200081A (en, 2012)
HR (1) HRP20030911A2 (en, 2012)
HU (1) HUP0304085A3 (en, 2012)
IL (1) IL157874A0 (en, 2012)
IS (1) IS6956A (en, 2012)
MA (1) MA27021A1 (en, 2012)
MX (1) MXPA03010365A (en, 2012)
MY (1) MY134123A (en, 2012)
NO (1) NO20035035L (en, 2012)
NZ (1) NZ528209A (en, 2012)
OA (1) OA12600A (en, 2012)
PA (1) PA8545001A1 (en, 2012)
PE (1) PE20021095A1 (en, 2012)
PL (1) PL366774A1 (en, 2012)
SK (1) SK13372003A3 (en, 2012)
TN (1) TNSN03112A1 (en, 2012)
UA (1) UA73421C2 (en, 2012)
UY (1) UY27287A1 (en, 2012)
WO (1) WO2002092597A1 (en, 2012)
ZA (1) ZA200307234B (en, 2012)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20000445B1 (hr) * 1997-12-31 2009-04-30 Pfizer Products Inc. Aril kondenzirani azapoliciklički spojevi
DK1448235T3 (da) * 2001-11-30 2007-07-02 Pfizer Prod Inc Orale, farmaceutiske sammensætninger af 5,8,14-triaza-tetracyclo[10.3.1.0(2,11).0(4.9)]-hexadeca-2(11),3,5,7,9-pentaen med kontrolleret frigivelse
JP2006528237A (ja) * 2003-05-20 2006-12-14 ファイザー・プロダクツ・インク バレニクリンの医薬組成物
US20050043407A1 (en) * 2003-08-22 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
WO2008060487A2 (en) * 2006-11-09 2008-05-22 Pfizer Products Inc. Polymorphs of nicotinic intermediates
US8440825B2 (en) 2008-03-06 2013-05-14 Medichem S.A. Fumaric acid salt of varenicline
EP2268639A2 (en) 2008-05-22 2011-01-05 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
RU2527970C2 (ru) * 2008-12-11 2014-09-10 Селл Терапьютикс,Инк. Цитрат 11-(2-пирролидин-1-ил-этокси)-14,19-диокса-5,7,26-триазатетрацикло[19.3.1.1(2,6).1(8,12)]гептакоза-1(25),2(26),3,5,8,10,12(27),16,21,23-декаена
US8080584B2 (en) 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
EP2440187A2 (en) 2009-06-10 2012-04-18 Actavis Group PTC ehf. Amorphous varenicline tartrate co-precipitates
RU2012102052A (ru) 2009-06-22 2013-11-20 Тева Фармасьютикал Индастриз Лтд. Твердые формы солей варениклина и способы их получения
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
CN104334561B (zh) 2012-04-13 2016-06-22 连云港金康和信药业有限公司 化合物jk12a及其制备
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
EP3756653A1 (en) 2019-06-28 2020-12-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Microparticulate varenicline citrate
JP2023520164A (ja) * 2020-03-16 2023-05-16 チョンドゥー サイマウント ファーマテック カンパニー リミテッド ５－ｈｔ３受容体モジュレーター、結晶形態、それらの製造方法及び使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20000445B1 (hr) * 1997-12-31 2009-04-30 Pfizer Products Inc. Aril kondenzirani azapoliciklički spojevi
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

Also Published As

Publication number Publication date
MY134123A (en) 2007-11-30
UY27287A1 (es) 2003-02-28
AP2002002522A0 (en) 2002-06-30
IL157874A0 (en) 2004-03-28
MA27021A1 (fr) 2004-12-20
WO2002092597A1 (en) 2002-11-21
JP2004529186A (ja) 2004-09-24
CN1509288A (zh) 2004-06-30
NZ528209A (en) 2004-09-24
HRP20030911A2 (en) 2004-02-29
CZ20032917A3 (cs) 2004-07-14
SK13372003A3 (sk) 2004-08-03
DE60205888D1 (de) 2005-10-06
EA200301120A1 (ru) 2004-02-26
JP4137645B2 (ja) 2008-08-20
US6787549B2 (en) 2004-09-07
HUP0304085A2 (en) 2004-04-28
NO20035035D0 (no) 2003-11-13
TNSN03112A1 (fr) 2005-12-23
ES2245731T3 (es) 2006-01-16
AR035889A1 (es) 2004-07-21
EP1390366B1 (en) 2005-08-31
PA8545001A1 (es) 2003-09-05
EE200300557A (et) 2004-04-15
UA73421C2 (en) 2005-07-15
IS6956A (is) 2003-09-15
ATE303386T1 (de) 2005-09-15
CA2446988A1 (en) 2002-11-21
AP1429A (en) 2005-06-13
EA005529B1 (ru) 2005-04-28
ZA200307234B (en) 2004-09-16
DOP2002000390A (es) 2003-03-15
PL366774A1 (en) 2005-02-07
OA12600A (en) 2006-06-09
HUP0304085A3 (en) 2005-09-28
NO20035035L (no) 2003-11-13
KR20040008175A (ko) 2004-01-28
MXPA03010365A (es) 2004-03-16
PE20021095A1 (es) 2002-12-14
BG108344A (bg) 2004-12-30
EP1390366A1 (en) 2004-02-25
DE60205888T2 (de) 2006-07-06
DZ3503A1 (en, 2012) 2002-11-21
US20030149091A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
GT200200081A (es) Sal citrato de 5,8,14-triazatetraciclo[10.3.1.0 2,11.0 4,9] hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de la misma
PA8580301A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
MXPA05009304A (es) Derivados de indol utiles para el tratamiento de enfermedades.
BG108207A (en) Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
MY138478A (en) Benzazepine derivatives for the treatment of neurological disorders
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
YU63703A (sh) 6-supstituisani pirido-pirimidini
UA83862C2 (ru) Производные тиазола как модуляторы рецепторов канабиноидов
BRPI0409611A (pt) derivados de piperazina e uso dos mesmos para o tratamento de doenças neurológicas e psiquiátricas
MY143390A (en) Sulfonamide derivatives for the treatment of diseases.
MY139690A (en) Sulfonamide derivatives for the treatment of diseases.
BRPI0410649A (pt) benzo(b) tiofeno 3-arilóxi e 3-heteroarilóxi substituìdos como agentes terapêuticos com atividade pi3k
AR022469A1 (es) Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias
WO2002102793A3 (en) Quinazolinediones as antibacterial agents
MXPA05013059A (es) Derivados de 2-amino-piridina como agonistas del adrenoceptor beta-2.
NO20064238L (no) Imidazolinderivater med CB1 agonistlsk aktivitet
TW200505865A (en) Compounds useful for the treatment of diseases
TW200514781A (en) Novel compounds
MXPA05012953A (es) Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
MXPA03010766A (es) Nuevos compuestos y composiciones como inhibicores de las catepsinas.
UA84300C2 (ru) ПРОИЗВОДНЫЕ ГЕКСА- И ОКТАГИДРОПИРИДО[1,2-a]ПИРАЗИНА С АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ОТНОСИТЕЛЬНО NK1
BR0110255A (pt) Cromenilmetil pirimidinadiaminas como agentes antibacterianos
MXPA04004450A (es) Nuevos compuestos y composiciones como inhibidores de catepsina s.
PA8558901A1 (es) Nuevos compuestos hexaciclicos
TW200621223A (en) Acyclic 1,3-diamines and uses therefor